Sensitivity analysis in cost-effectiveness studies: From guidelines to practice

PharmacoEconomics

Volumn 29, Issue 4, 2011, Pages 297-314

  Jain, Rahul ^a   Grabner, Michael ^b   Onukwugha, Eberechukwu ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cost effectiveness; Modelling; Probabilistic sensitivity analysis; Sensitivity analysis

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; STANDARDIZATION; STATISTICAL MODEL; UNCERTAINTY;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; GUIDELINES AS TOPIC; HUMANS; UNCERTAINTY;

EID: 79952663516     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584630-000000000-00000     Document Type: Article

References (64)

1. Neumann P. Using cost-effectiveness analysis to improve health care: opportunities and barriers. New York: Oxford University Press, 2005
2. Weinstein M, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716-21 (Pubitemid 8066534)
3. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302 (13): 1437-43
4. Manning W, Fryback D, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In: Gold M, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 247-75
5. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging the-ory with practice. London: Oxford University Press, 2001
6. Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500 (Pubitemid 30398806)
7. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assess-ment. Pharmacoeconomics 2006; 24(4): 355-71
8. Australia Commonwealth Department ofHealth and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Com-mittee (PBAC): including major submissions involving eco-nomic analyses. Canberra (ACT): Australia Commonwealth Department ofHealth and Ageing, 2002
9. European Network of Health Economic Evaluation Databases. Methodological guide. Paris: EURONHEED, 2004
10. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technol-ogies: Canada. 3rd ed. Ottawa (ON): CADTH, 2006
11. National Institute for Health and Clinical Excellence. Guide to the methods oftechnology appraisal. London: NICE, 2008
12. Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009; 13 (29): iii, ix-xi, 1-61
13. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313 (7052): 275-83 (Pubitemid 26254740)
14. Drummond M, Richardson WS, O'Brien BJ, et al. User's guides to medical literature: XIII. How to use an article on economic analysis ofclinical practice: A. Are the results of the study valid? JAMA 1997; 277 (19): 1552-7 (Pubitemid 27213306)
15. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation ofhealth care programmes. New York: Oxford University Press, 2005
16. Goetghebeur M, Rindress D. Towards a European consensus on conducting and reporting health economic eval-uations: a report from the ISPOR Inaugural European Conference. Value Health 1999; 2 (4): 281-7
17. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeco-nomics 2000; 17 (5): 461-77 (Pubitemid 30398805)
18. Soto J. Health economic evaluations using decision analytic modeling: principles and practices. Utilization of a check-list to their development and appraisal. Int J Technol As-sess Health Care 2002; 18 (1): 94-111 (Pubitemid 34408532)
19. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6 (1): 9-17 (Pubitemid 36228345)
20. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health 2001; 4 (3): 225-50 (Pubitemid 32661267)
21. Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies: an appraisal of the literature. Pharmacoeconomics 1997; 11 (1): 75-88 (Pubitemid 27032252)
22. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review ofpublished studies. Health Econ 1995; 4 (5): 355-71
23. Briggs A, Gray A. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3 (2): 1-134
24. Kruper L, Kurichi J, Sonnad S. Methodologic quality of cost-effectiveness analyses of surgical procedures. Ann Surg 2007; 245 (1): 147-51 (Pubitemid 46035446)
25. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992; 116 (3): 238-44
26. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000; 132 (12): 964-72 (Pubitemid 30397597)
27. Gerard K, Smoker I, Seymour J. Raising the quality ofcostutility analyses: lessons learnt and still to learn. Health Policy 1999; 46 (3): 217-38 (Pubitemid 29115071)
28. Schackman BR, Gold HT, Stone PR, et al. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? Pharmacoeconomics 2004; 22 (5): 293-300 (Pubitemid 38553700)
29. Mandelblatt JS, Fryback DG, Weinstein MC. Assessing the effectiveness of health interventions. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
30. Lang DL, Lopert R, Hill SR. Use ofpharmacoeconomics in prescribing research: part 5. Modelling: beyond clinical trials. J Clin Pharm Ther 2003; 28 (5): 433-9 (Pubitemid 37352454)
31. Beck J, Pauker S. The Markov process in medical prognosis. Med Decis Making 1983; 3 (4): 419-58 (Pubitemid 14196965)
32. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233-53
33. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1 (1): 71-6
34. Brisson M, Edmunds W. Impact ofmodel, methodological, and parameter uncertainty in the economic analysis ofvac-cination programs. Med Decis Making 2006; 26 (5): 434-46 (Pubitemid 44410295)
35. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, et al. The measurement of patients' values in medicine. Med Decis Making 1982; 2 (4): 449-62 (Pubitemid 13066277)
36. Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5 (1): 1-30 (Pubitemid 16098443)
37. Hoch J, Briggs A, Willan A. Something old, somethingnew, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11 (5): 415-30 (Pubitemid 34752613)
38. Wooldridge J. Econometric analysis of cross section and panel data. Cambridge (MA): MIT Press, 2002
39. Journal Citation Reports®. Science edition. New York: Thomson Reuters, 2008
40. Groot Koerkamp B, Weinstein MC, Stijnen T, et al. Uncertainty and patient heterogeneity in medical decision models. Med Decis Making 2010; 30 (2): 194-205
41. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3 (2): 95-104
42. Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 2006; 15 (4): 373-81
43. Pasta D, Taylor J, Henning J. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 1999; 19 (3): 353-63 (Pubitemid 29321277)
44. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a prac-tical approach. Med Decis Making 1985; 5 (2): 157-77 (Pubitemid 16130640)
45. Briggs A, O'Brien B, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377-401 (Pubitemid 34508080)
46. Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application ofmethods. Value Health. Epub 2009 Jan 9
47. Gold M, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
48. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 799-806
49. Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold M, Siegel JE, Russell LB, et al., editors. Cost-effec-tiveness in health and medicine. New York: Oxford University Press, 1996: 214-46
50. D'Agostino R, Belanger A, D'Agostino Jr RJ. A suggestion for using powerful and informative tests ofnormality. Am Stat 1990; 44 (4): 316-21
51. Jarque C, Bera A. Efficient tests for normality, homoscedasticity and serial independence of regression residuals. Econ Lett 1980; 6 (3): 255-9
52. Ramsey J. Tests for specification errors in classical linear least-squares regression analysis. J Royal Statist Soc Series B 1969; 31 (2): 350-71
53. Breusch T, Pagan A. Simple test for heteroscedasticity and random coefficient variation. Econometrica 1979; 47 (5): 1287-94
54. Goldfeld S, Quandt R. Some tests for homoscedasticity. J Am Stat Assoc 1965; 60: 539-47
55. Engle R. Autoregressive conditional heteroscedasticity with estimates of the variance of United Kingdom inflations. Econometrica 1982; 50: 987-1008
56. Zietz J. Heteroskedasticity and neglected parameter heterogeneity. Oxf Bull Econ Stat 2001; 63 (2): 263-73 (Pubitemid 33282214)
57. Zietz J. Detecting neglected parameter heterogeneity with Chow tests. Appl Econ Lett 2006; 13 (6): 369-74
58. Williams I, McIver S, Moore D, et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008; 12 (7): iii, ix-x, 1-175
59. Briggs AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol 2004; 16 (6): 551-61 (Pubitemid 38703863)
60. Lehman AF, Dixon L, Hoch JS, et al. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry 1999 Apr; 174: 346-52 (Pubitemid 29179718)
61. Hoch J, Dewa C. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay mat-ters. Pharmacoeconomics 2007; 25 (10): 807-16 (Pubitemid 47481632)
62. King JE. Software solutions for obtaining a Kappa-type statistic for use with multiple raters. Annual Meeting of the Southwest Educational Research Association; 2004 Feb 5-7; Dallas (TX) [online]. Available from URL: http://www.ccit.bcm.tmc.edu/jking/homepage/genkappa.doc [Ac-cessed 2010 Dec 25]
63. King J, Wallace J. Calculating a generalized Kappa statistic for use with multiple raters. 2009 [online]. Available from URL: http://www.ccit.bcm.tmc. edu/jking/homepage/kap pa1.xls [Accessed 2010 Dec 25]
64. Fleiss J, Nee J, Landis J. Large sample variance of kappa in the case ofdifferent sets ofraters. Psychol Bull 1979; 86: 974-7